HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Staels, B. Articles by Verhoeven, G. Search for Related Content PubMed PubMed Citation Articles by Staels, B. Articles by Verhoeven, G. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 30, 1137-1145, Copyright © 1989 by Lipid Research, Inc.

ARTICLES

Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine

B Staels, J Auwerx, L Chan, A van Tol, M Rosseneu and G Verhoeven
Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Gasthuisberg, Katholieke Universiteit Leuven, Belgium.

The influence of development and ethinylestradiol (EE) on apolipoprotein (apo) A-I, A-II, and E mRNA in rat liver and intestine was studied by dot blot hybridization and Northern blot analysis. ApoA- I mRNA levels were maximal in the perinatal period and declined after day 15. An opposite trend was noted for the apoA-II mRNA levels, whereas apoE mRNA remained fairly constant. Liver apoA-I mRNA levels increased after ovariectomy (OVX). A further rise was observed when EE was given at 2000 micrograms/day. When the influence of OVX and EE was controlled for food intake by pair-feeding, OVX still increased hepatic apoA-I mRNA. The rise in liver apoA-I mRNA after EE, however, was no longer significant. Under the same conditions OVX slightly increased intestinal apoA-I mRNA. EE (2000 micrograms/day) decreased intestinal apoA-I mRNA to 80% of the pair-fed controls. Liver apoA-II mRNA levels did not change after OVX when the animals were fed ad libitum, but decreased slightly when the rats were pair-fed. EE caused a dose- dependent decrease in liver apoA-II mRNA, irrespective of food intake. None of these treatments caused any change in liver apoE mRNA levels. Serum apoA-I levels increased upon OVX, while serum apoE did not change. EE provoked a dose-dependent decrease of both apolipoproteins in serum. In conclusion: 1) Changes in food intake play an important role in the in vivo effects of estrogens on apolipoprotein mRNA levels. 2) The stimulatory effect of OVX on hepatic apoA-I mRNA as well as the inhibitory effect of EE on hepatic apoA-II mRNA are independent of food intake.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Grenier, F. S. Maupas, J.-F. Beaulieu, E. Seidman, E. Delvin, A. Sane, E. Tremblay, C. Garofalo, and E. Levy Effect of retinoic acid on cell proliferation and differentiation as well as on lipid synthesis, lipoprotein secretion, and apolipoprotein biogenesis Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1178 - G1189. [Abstract] [Full Text] [PDF]

				D. Sauvaget, V. Chauffeton, S. Dugue-Pujol, A.-D. Kalopissis, I. Guillet-Deniau, F. Foufelle, J. Chambaz, A. Leturque, P. Cardot, and A. Ribeiro In Vitro Transcriptional Induction of the Human Apolipoprotein A-II Gene by Glucose Diabetes, March 1, 2004; 53(3): 672 - 678. [Abstract] [Full Text] [PDF]

				L. Cui, N. W. Schoene, L. Zhu, J. C. Fanzo, A. Alshatwi, and K. Y. Lei Zinc depletion reduced Egr-1 and HNF-3beta expression and apolipoprotein A-I promoter activity in Hep G2 cells Am J Physiol Cell Physiol, August 1, 2002; 283(2): C623 - C630. [Abstract] [Full Text] [PDF]

				I. P. Torra, V. Tsibulsky, F. Delaunay, R. Saladin, V. Laudet, J.-C. Fruchart, V. Kosykh, and B. Staels Circadian and Glucocorticoid Regulation of Rev-erb{alpha} Expression in Liver Endocrinology, October 1, 2000; 141(10): 3799 - 3806. [Abstract] [Full Text] [PDF]

				J. F. Couse and K. S. Korach Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us? Endocr. Rev., June 1, 1999; 20(3): 358 - 417. [Abstract] [Full Text]

				A. Mamontova, S. Seguret-Mace, B. Esposito, C. Chaniale, M. Bouly, N. Delhaye-Bouchaud, G. Luc, B. Staels, N. Duverger, J. Mariani, et al. Severe Atherosclerosis and Hypoalphalipoproteinemia in the Staggerer Mouse, a Mutant of the Nuclear Receptor ROR{alpha} Circulation, December 15, 1998; 98(24): 2738 - 2743. [Abstract] [Full Text] [PDF]

				D. C. Harnish, M. J. Evans, M. S. Scicchitano, R. A. Bhat, and S. K. Karathanasis Estrogen Regulation of the Apolipoprotein AI Gene Promoter through Transcription Cofactor Sharing J. Biol. Chem., April 10, 1998; 273(15): 9270 - 9278. [Abstract] [Full Text] [PDF]

				R. A. K. Srivastava, N. Srivastava, M. Averna, R. C. Lin, K. S. Korach, D. B. Lubahn, and G. Schonfeld Estrogen Up-regulates Apolipoprotein E (ApoE) Gene Expression by Increasing ApoE mRNA in the Translating Pool via the Estrogen Receptor alpha -Mediated Pathway J. Biol. Chem., December 26, 1997; 272(52): 33360 - 33366. [Abstract] [Full Text] [PDF]

				N. Vu-Dac, P. Gervois, T. Grotzinger, P. De Vos, K. Schoonjans, J.-C. Fruchart, J. Auwerx, J. Mariani, A. Tedgui, and B. Staels Transcriptional Regulation of Apolipoprotein A-I Gene Expression by the Nuclear Receptor RORalpha J. Biol. Chem., September 5, 1997; 272(36): 22401 - 22404. [Abstract] [Full Text] [PDF]

				S. G. Lundeen, J. M. Carver, M.-L. McKean, and R. C. Winneker Characterization of the Ovariectomized Rat Model for the Evaluation of Estrogen Effects on Plasma Cholesterol Levels Endocrinology, April 1, 1997; 138(4): 1552 - 1558. [Abstract] [Full Text] [PDF]

				R. F. Kauffman, W. R. Bensch, R. E. Roudebush, H. W. Cole, J. S. Bean, D. L. Phillips, A. Monroe, G. J. Cullinan, A. L. Glasebrook, and H. U. Bryant Hypocholesterolemic Activity of Raloxifene (LY139481): Pharmacological Characterization as a Selective Estrogen Receptor Modulator J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 146 - 153. [Abstract] [Full Text]

				S. Seguret-Mace, M. Latta-Mahieu, G. Castro, G. Luc, J.-C. Fruchart, E. Rubin, P. Denefle, and N. Duverger Potential Gene Therapy for Lecithin-Cholesterol Acyltransferase (LCAT)–Deficient and Hypoalphalipoproteinemic Patients With Adenovirus-Mediated Transfer of Human LCAT Gene Circulation, November 1, 1996; 94(9): 2177 - 2184. [Abstract] [Full Text]

				B Staels and J Auwerx Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models Development, January 8, 1992; 115(4): 1035 - 1043. [Abstract] [PDF]

				J. Ladias and S. Karathanasis Regulation of the apolipoprotein AI gene by ARP-1, a novel member of the steroid receptor superfamily Science, February 1, 1991; 251(4993): 561 - 565. [Abstract] [PDF]

				J. Dallongeville, E. Bauge, A. Tailleux, J. M. Peters, F. J. Gonzalez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-activated Receptor alpha Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil J. Biol. Chem., February 9, 2001; 276(7): 4634 - 4639. [Abstract] [Full Text] [PDF]